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Background: Progressive Hemifacial Atrophy (PHA) is an acquired, typically unilateral, facial distortion with unknown
etiology. The true incidence of this disorder has not been reported, but it is often regarded as a subtype of localized
scleroderma. Historically, a debate existed whether PHA is a form of linear scleroderma, called morphea en coup de
sabre (ECDS), or whether these conditions are inherently different processes or appear on a spectrum (; Adv Exp Med
Biol 455:101–4, 1999; J Eur Acad Dermatol Venereol 19:403–4, 2005). Currently, it is generally accepted that both
diseases exist on a spectrum of localized scleroderma and often coexist.
The pathogenesis of PHA has not been delineated, but trauma, autoimmunity, infection, and autonomic dysregulation
have all been suggested. The majority of patients have initial manifestations in the first two decades of life; however,
late presentations in 6th and 7th decades are also described [J Am Acad Dermatol 56:257–63, 2007; J Postgrad Med
51:135–6, 2005; Neurology 61:674–6, 2003]. The typical course of PHA is slow progression over 2-20 years and eventually
reaching quiescence.
Systemic associations of PHA are protean, but neurological manifestations of seizures and headaches are common
[J Am Acad Dermatol 56:257–63, 2007; Neurology 48:1013–8, 1997; Semin Arthritis Rheum 43:335–47, 2013]. As in
many rare diseases, standard guidelines for imaging, treatment, and follow-up are not defined.
Methods: This review is based on a literature search using PubMed including original articles, reviews, cases and
clinical guidelines. The search terms were “idiopathic hemifacial atrophy”, “Parry-Romberg syndrome”, “Romberg’s
syndrome”, “progressive hemifacial atrophy”, “progressive facial hemiatrophy”, “juvenile localized scleroderma”,
“linear scleroderma”, and “morphea en coup de sabre”. The goal of this review is to summarize clinical findings,
theories of pathogenesis, diagnosis, clinical course, and proposed treatments of progressive hemifacial atrophy
using a detailed review of literature.
Inclusion- and exclusion criteria: Review articles were used to identify primary papers of interest while retrospective
cohort studies, case series, case reports, and treatment analyses in the English language literature or available
translations of international literature were included.
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Romberg’s syndrome, Morphea, SclerodermaHistory and nomenclature
First described by Parry in 1825, and Romberg in 1846,
this constellation of craniofacial findings was labeled as
progressive hemifacial atrophy by Eulenberg in 1871.
Other names used to describe this disorder include
Parry-Romberg syndrome (PRS), idiopathic hemifacial
atrophy, progressive facial hemiatrophy (PFH), and
Romberg’s syndrome. Interestingly, evidence of the* Correspondence: Tollefson.Megha@mayo.edu
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unless otherwise stated.disease dates back to ancient Egypt with mummies
exhibiting craniofacial dysmorphism consistent with
PHA [1-11].Epidemiology
Studies to determine true incidence and epidemiologic
characteristics of PHA have been elusive due to the rarity
of the disease, a lack of standardized criteria for diagnosis
[12], and the overlapping features of PHA and ECDS [13].
PHA is more often seen in the female sex, and simi-
larly, morphea is typically described as having a female
predilection [14]. In one recent series of 32 patients,
66% were female [15]. This is a similar ratio seen intral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and another with 22 patients [1,13]. Older studies have
shown a slightly higher female prevalence. In the
aforementioned review of 772 cases, the female to male
ratio of 3:1 [16]. This was replicated in a recent global
survey of PHA (3:1); however, there may have been
some responder bias leading to the higher female
prevalence [5].
Clinical course and associations/complications
PHA usually presents in the first 20 years of life, al-
though, late-onset disease has also been described
[4,15,17,18]. A Mayo Clinic study of 54 patients, group-
ing ECDS and PHA, showed an average age of onset of
13.6 years with a median of 10.5 years and a range of 0.3
to 75 years. These findings have been corroborated by
other large reports [1,5,13,17,19].
After initial presentation, the disorder is usually slowly
progressive but self-limited [12]. The disease typically
“burns out” in 2-10 years before becoming stationary
[16,20,21]. While a majority of patients experience halt-
ing of the facial atrophy, in the aforementioned global
internet survey, 26% of patients reported disease acceler-
ation. 68% of these cases were women and experienced
worsening of facial hemiatrophy during pregnancy (9
women) or after childbirth (8 women). Of the progres-
sive disease cases, stress (26%) and surgery (8%) were
identified as possible triggers for acceleration [5]. How-
ever, the level of disease activity of each responder could
not be assessed by the author. The slowly progressive
nature of the disease, and at which point patients are onFigure 1 Progressive Hemifacial Atrophy. a: Hemifacial atrophy affecting
b: Left-sided sunken appearance secondary to subcutaneous and osseous athe spectrum of disease activity, must be taken into ac-
count to distinguish disease acceleration versus normal
evolution.
Clinical description
PHA refers to hemifacial atrophy of the skin and cranio-
facial tissue inferior to the forehead, typically involving
dermatomes of one or more branches of the fifth cranial
nerve [12,22]. The atrophy affects subcutaneous tissue,
fat, muscle, and osteocartilaginous structures creating a
sunken hemiface appearance [12]. (Figure 1a and b)
Epidermal cutaneous involvement is minimal, but the
tongue, gingiva, teeth, and palate may also be involved
[13,16,18,23].
ECDS manifests as a lesion of linear depression gener-
ally located on the frontoparietal scalp or paramedian
forehead [24]. It is usually a linear unilateral depression,
which may extend below the forehead, involving the
nose, medial cheek, and sometimes the upper lip,
although rare bilateral cases have been described. In-
volved skin is hyperpigmented, shiny, firm, and displays
alopecia [13,25]. The atrophic shiny plaque may be asso-
ciated with the scalp or madarosis. Hence, a resemblance
of this furrow to a “stroke from a sword”. (Figure 2a and
b) While the two may coexist in the same patient,
(Figure 3a and b) clinical features are typically used to
distinguish PHA from ECDS [12,21,26].
PHA is associated with multiple extracutaneous find-
ings, of which neurologic complications are the most
common. Seizures and headaches are the most common
neurologic symptoms in patients with PHA. In patientssubcutaneous tissue, fat, muscle, and osteocartilaginous structures.
trophy.
Figure 2 Morphea En Coup de Sabre. a: Atrophic shiny plaque with scalp and eyebrow alopecia. b: Scalp linear alopecia in a patient with ECDS.
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originating in the ipsilateral cerebral cortex are most often
seen, and can be refractory to treatment. In patients with
other forms of localized and systemic scleroderma, seizures,
headaches, and other central nervous system findings may
sometimes be seen, but peripheral and autonomic neuropa-
thies tend to predominate [1,7,15,17,27-30].
Cranial neuropathies involving cranial nerves III, V, VI,
and VII, have also been described in patients with PHA
[19,31-34]. Secondary trigeminal neuralgia has been re-
ported due to impingement of the nerve by destructionFigure 3 Morphea ECDS and PHA. a: Patient demonstrating concurrent righ
morphea ECDS and PHA 2 years later.of bony structures, as well as vascular inflammation and
damage resulting in facial pain that can be chronic and
poorly responsive to treatment [35,36]. Additionally,
speech may be affected in PHA patients resulting in dys-
arthria or aphasia [37,38]. Cognitive impairment and an
increase in behavioral disorders have also been noted
[15,39]. Depending on the degree of atrophy, changes to
intracranial tissue and vessels may also result in hemi-
paresis, dysesthesias, and paresthesias [34,37,40-42].
Vascular damage in the form of infarction, hemorrhage,
and white matter hyper-density can be seen in patientst ipsilateral morphea ECDS and PHA. b: Same patient with concurrent
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[1,41,43]. Dysplastic vessel formation has also been
demonstrated in damaged areas of the cerebellum in
PHA patients and may also contribute to intracranial
findings [44,45]. Vascular damage, dysplastic vessels,
and changes in vessel diameter may lead to cerebellar
atrophy and production of neurologic symptoms. Some
of this may be reversible with treatment [39,46]. Rare
intracranial vascular malformations may be seen in
patients with PHA and usually consist of dilation of
intracranial blood vessels [40,47-49].
Ocular problems may be seen in patients with PHA;
these can result in mild visual impairment to blindness
[50]. Because of atrophy involving deeper tissue, enophthal-
mos has been frequently described and often results in loss
of function of the orbitalis muscle. Other tissues altered by
the atrophic process include the eye itself, the eyelid, and
other extraocular muscles. The atrophy may be so severe
that restrictive strabismus may result [51-54]. Additionally,
patients with PHA have sometimes been noted to have
retinal vasculitis, thus further supporting a possible
vascular pathogenesis. Less common findings of neuror-
etinitis, uveitis, papillitis, glaucoma, cataracts, pigmen-
tary changes of the retina and optical fundus, and iris
heterochromia have also been demonstrated in some
patients with PHA [51,55-61].
Teeth abnormalities and involvement of the mandible
and masticatory muscles is frequently seen in patients
with PHA. Shorter crowns and roots and crowding of
teeth have been seen, as well. Secondary to maxillary
and mandibular hypoplasia, chewing, smiling, and speech
may be affected, although hemiatrophy and disturbances
of other oral structures such as the tongue, lips, salivary
glands, and gingiva can also contribute to the develop-
ment of these symptoms. In those with dental involve-
ment, infection is frequent. Pain secondary to masticatory
muscle spasm, temporomandibular joint pain, and locking
of the jaw has also been reported [52,62-69].
Skeletal hypoplasia of involved areas of the skull is
common, although the clinical significance of this is
unknown [52,70]. Atrophy of the extremities, both ipsi-
laterally and contralaterally, as well as the trunk, has
been described in rare cases [12,18,71-73]. Although
the reason for this peripheral atrophy is unknown, one
such affected patient had normal magnetic resonance
angiography in the atrophic limb with only reduction in
volume of muscle and fat, making an ischemic or vascu-
lar process unlikely in that case [12].
Relationship of morphea ECDS and PHA
Multiple studies have tried distinguishing PHA and ECDS
based on clinical and histopathologic criteria [2,13,19].
Thomas Lehman mentioned two key clinically diffe-
rentiating factors: paramedian atrophy of PHA withoutsignificant induration of the overlying skin and associated
atrophy extending down the side of the face with tongue
and mandibular involvement. ECDS, in his opinion, is as-
sociated with cutaneous induration in the area of the scalp
and does not extend below the forehead [74,75]. His dis-
claimer, that most cases lack clear distinction, is echoed by
multiple authors and is consistent with the thought that
these entities lie on the same spectrum of disease [2,3].
Some authors have proposed that these two diseases
may be differentiated clinically and histologically. In one
series of 13 cases of ECDS and 9 cases of PHA, cases
were retrospectively evaluated using photos and histo-
pathologic slides [13]. The authors found that the main
clinical difference between the two entities was cutane-
ous sclerosis (present in 8/13 of ECDS and 0 PHA),
hyperpigmentation, and alopecia in ECDS, versus total
hemifacial involvement and ocular changes in PHA.
Histopathologically, however, there was significant over-
lap as connective tissue fibrosis was seen in all cases
with ECDS and in 2/9 cases of PHA. Adnexal atrophy
was seen in 11/13 of ECDS and 3/9 of PHA while mono-
nuclear cell infiltrates was present in all ECDS biopsies
and 6/9 PHA. Another case series that followed 71 ECDS
and PHA patients over a 20 year timespan, found that the
clinical morphological pattern of the disease presentation
changed progressively such that clear distinctions between
the two entities often disappeared over time [3] (Table 1).
Duymaz et al. proposed clinical criteria when evaluat-
ing a patient with facial atrophy. PHA was suggested
when the patient presented with unilateral facial atrophy
and lacked previous induration, inflammation, or cuta-
neous atrophy and sclerosis. Scleroderma ECDS was
favored if unilateral band-like changes of sclerosis with
hyperpigmentation in the frontoparietal area with associ-
ated induration was noted. Involvement of the area
above the eyebrow without extension inferiorly, with
cutaneous sclerosis and marked deformity, was noted to
better describe ECDS [12]. However, histopathologic
findings were not examined.
Often, clinical findings of both are present in the same
individual [1,17,43,74,76]. In fact, 28 to 42% of patients
have been reported to have coexisting ECDS and PHA
[1,17,76]. In one review of 235 patients with localized
scleroderma at Mayo Clinic from 1923 to 1954, facial
hemiatrophy was associated with 41.3% of the 29 local-
ized scleroderma cases involving the frontal, frontoparie-
tal, or facial regions [77]. A large literature review of 772
cases mentioned ECDS as a potential initial presentation
in some cases. It is possible that some of these patients
may have had coexisting disease or only ECDS [16]. In
another evaluation of 58 cases of ECDS, 20 developed
signs of PHA [2]. Additionally, progression or transition
of ECDS into PHA in the same physical location has also
been illustrated in a handful of cases [2,3].
Table 1 Comparison of morphea ECDS and PHA
Morphea en Coup de Sabre Progressive Hemifacial Atrophy
Average Age (years) 10 13.6
Gender (F:M) 2:1 – 3:1 3:1
Clinical Features -Cutaneous induration/sclerosis -Paramedian atrophy
-Scalp to forehead^ -No overlying skin induration
-Hyperpigmentation -Atrophy may extend down entire face
-Alopecia (scalp/eyebrow)
Histopathologic Features~ -Dermal Sclerosis -Dermal sclerosis
-Adnexal atrophy -Fat atrophy
-Mononuclear cell infiltrates* -Decrease in adnexal structures
-Mononuclear cell infiltrates*
Extracutaneous Associations -Atrophy subcutaneous tissue, fat, muscle, and osteocartilaginous
structures






*Histopathologic features depend on disease activity.
^May extend below the forehead and involve the nose, medial cheek, and upper lip.
~Connective tissue fibrosis, adnexal/fat atrophy, and mononuclear cell infiltrates all seen ECDS > PHA although considerable overlap may be seen.
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authors concluded that their findings support these two
entities as being on a spectrum of disease. 71.4% of the
28 patients with PHA in their study had facial sclerosis,
with 53.6% having en coup de sabre lesions. Addition-
ally, they found that of the 41 patients with ECDS, 36.6%
also had PHA. Histologically, the biopsy specimens of
PHA patients who did not have cutaneous sclerosis
showed findings consistent with morphea [1]. Several
prior studies had similar results [17,78].
In summary, while there may be some features that
clinically distinguish ECDS from PHA, clinical and
histopathologic findings may often overlap in the same
patient, thus supporting the belief that ECDS and PHA
fall on the same spectrum of disease.
Diagnosis
The diagnosis of PHA is a largely clinical one, supported
by other findings such as histopathology and imaging.
No universal diagnostic criteria are accepted. As dis-
cussed above, the characteristic clinical features of PHA
which allow for its diagnosis is the presence of unilateral
idiopathic facial atrophy, typically involving the lower
face, without significant epidermal change. Deeper
involvement of bone, teeth, tongue, and gingiva may also
be present (Table 1). Patients are typically classified as
having ECDS if they demonstrate linear scleroderma of
the frontoparietal scalp with involvement of medial or
paramedian forehead with possible extension of thesclerosis onto the scalp, nasal sidewall, and maxilla [1].
The cutaneous sclerosis, with possible hyperpigmen-
tation and alopecia of ECDS, has been suggested as a
potential differentiating factor between PHA and ECDS
in those who desire to distinguish between them [13].
However, the boundaries between these entities are
blurred as seen in patients with cutaneous sclerosis
developing more significant atrophy than typically seen
in ECDS, and conversely, those with atrophy without
significant epidermal change, going on to develop cuta-
neous sclerosis [3].
Histopathology of affected areas in PHA, with or with-
out clinical findings of a sclerotic process, shows homog-
enized dermal sclerosis, fat atrophy, decrease in adnexal
structures, and perivascular plasma cells and lympho-
cytes [1,13,79] (Table 1). On the other hand, biopsy
specimens in ECDS have been noted to show hyperpig-
mentation, alopecia, and cutaneous sclerosis. Atrophy of
epidermis, dermis, adnexal structures and subcutaneous
tissue has been seen in both PHA (with and without der-
mal sclerosis) and ECDS. More specific changes may be
seen in biopsy specimens of patients with PHA includ-
ing: sparse to exuberant lymphocytic infiltrates in the
dermis, and degenerative changes of vascular endothelium
have also been noted in some studies [1,2,13,17,78,80,81].
Hence, biopsies often may not be helpful in the diagnosis
of these entities. Since skin biopsy is infrequently done
in cases of PHA, photographical records should be
maintained and followed throughout the duration of
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plateaus, photographical evaluation is helpful in follow-
ing the disease course. Additionally, if rapid changes in
skin induration or overall clinical presentation are
noted, a biopsy may be considered. Electroencephalo-
gram (EEG) changes may be seen in patients who have a
known seizure disorder and also in those who do not.
EEG findings may or may not be associated with intra-
cranial structural or imaging changes [7,30].
Laboratory work up of patients with PHA, as well as
other types of localized scleroderma, tends to be largely
unrevealing. A positive anti-nuclear antibody is the most
common laboratory abnormality, with approximately
25-52% of patients having an elevated titer [17,22,23,78].
Serology for rheumatoid factor, anti-Scl-70, C-reactive
protein (CRP), anti-dsDNA antibody, extractable nuclear
antigen screening, genotyping for HLA-B27, and anti-
cardiolipin antibodies are rarely abnormal and of limited
value in PHA patients. Rheumatoid factor has been
shown to be elevated in localized scleroderma with
extracutaneous involvement and those with arthritis.
However, it is currently unknown whether any PHA
patients regularly demonstrate an elevated rheumatoid
factor [22,23]. Peripheral eosinophilia and an elevated
erythrocyte sedimentation rate have also been reported
in association with localized scleroderma, but not with
PHA [22,23].
Ultrasound can be used to detect presence of sclerosis,
monitor disease activity, and treatment progress by
measuring dermal thickness and echogenicity of the
affected areas. Color Doppler ultrasound has the added
benefit of measuring dermal blood flow, an increase of
which indicates active disease. In patients with PHA,
assessment of the ipsilateral parotid gland and salivary
glands may also reveal increased blood flow and aFigure 4 MRI of Progressive Hemifacial Atrophy. a: Coronal view from
structures. b: Axial view from MRI demonstrating left hemifacial atrophy ofhypoechoic appearance, indicating inflammation of the
glands and active disease [82-84].
Due to the frequency of neurologic complications in
PHA, baseline imaging may be performed, particularly
in those patients that have neurologic symptoms. Typical
findings on MRI show hyperintense white matter lesions
on T2-weighted sequences. These are most prominent
ipsilaterally but are often seen bilateral despite lack of
skin involvement on the contralateral side. (Figure 4a
and b) These findings often do not progress despite pro-
gressive skin and skeletal involvement. Cerebral atrophy,
encephalomalacia, and cystic degeneration have been
seen on intracranial imaging of patients with PHA [37].
Computed tomography (CT) scanning may also be used,
but is less useful for evaluation of brain parenchyma
than MRI. Typically, calcifications and changes in dens-
ity of white matter can be seen on CT [15,30,85].
Whether or not abnormalities are demonstrated on
MRI, not all patients will have corresponding clinical
neurologic findings. Additionally, epileptic activity may
occur prior or in the absence of any abnormal findings
on MRI [30]. Skin findings are also not predictive of
CNS involvement [15,19,85]. Because a direct correlation
with CNS symptoms, skin findings, and MRI is not
always demonstrated, clinical evaluation on an individual
case-by-case basis is necessary to determine the need for
imaging, whether at baseline, or in follow-up [30,37,85].
Clinically silent white matter findings do occur [86].
Determining the significance of these may be challenging.
Single-photo emission CT (SPECT) may be a unique way
to test the regional blood flow in the presumingly involved
area, as regional blood flow hypoperfusion in the parie-
tooccipital area of the affected hemisphere has been
described in PHA patients with temporal lobe epilepsy
[87]. Conversely, relative increases in regional cerebralMRI demonstrating left hemifacial atrophy of soft tissue and osseous
soft tissue and osseous structures.
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SPECT may be associated with to preserved cortical func-
tion and normal psychomotor development [86]. Even if
extensive white matter abnormalities are demonstrated on
MRI, preserved cortical function may be demonstrated by
SPECT, proton MR spectroscopy (1H-MR spectroscopy),
and diffuse tensor imaging (DTI) [15]. These findings were
confirmed in an analysis of 19 PHA and 7 ECDS patients
with MRI, angio-MRI, and SPECT for CBF [19]. In this
study, the authors found that CNS involvement in patients
with PHA may be seen irrespective of when cutaneous
indurations were first noted clinically, and a diagnosis of
PHA was made. Furthermore, the SPECT may be abnor-
mal in PHA and ECDS whose MRI findings were unre-
vealing [19]. While observation of CNS symptoms and
initial evaluation with MRI when indicated are often
favored, the addition of a CBF analysis such as SPECT
may give additional detail on the overall CNS involvement
and prognosis in this patient population.
If there is a suspicion of a seizure disorder, electro-
encephalography may be done. In those patients with
EEG abnormalities, findings are usually ipsilateral to the
clinical involvement and most commonly show localized
activity [1,30,88].
As discussed above, ocular manifestations of PHA can
be potentially threatening to vision and are common.
Ophthalmology should therefore be consulted for evalu-
ation of vision, restrictive strabismus, ocular muscle
strength, glaucoma, and inflammatory pathologies asso-
ciated with the eye and PHA [50,51,61]. Ocular imaging
has demonstrated retinal edema and optical disc swelling
in some patients, which likely also contributes to visual
impairment and loss [89].
Dental involvement in PHA is common, making early
evaluation critical in reducing deformity and related
complications to the teeth, mandible, maxilla, and other
oral structures. Serial panoramic radiographs and photo-
graphs can be useful in monitoring disease progress until
there is stabilization of disease. This can also assist in
planning for surgery and orthodontic appliances [71,90].
Etiopathogenesis
A leading theory is that PHA is an autoimmune disorder.
This is supported by the presence of other autoimmune
conditions such as systemic lupus erythematosus (SLE),
generalized myopathy, and rheumatoid arthritis (RA) in
some patients with PHA [91-97]. Additionally, 17% and
10% of survey respondents with PHA to a survey de-
scribed a medical history of vitiligo and thyroid dysfunc-
tion, respectively [5]. Other autoimmune conditions seen
in these responders were inflammatory bowel disease
(5%), RA (4%), ankylosing spondylitis (2%), and SLE (2%)
[5]. The possible autoimmune etiology is also supported
serologically due to the frequent presence of anti-nuclearantibodies, although serologies are of limited use in diag-
nosis, as discussed above.
Another leading theory in the pathogenesis of morphea
form disorders such as PHA is that of vascular dysfunc-
tion. Vascular changes may invoke collagen production
and extracellular matrix proliferation seen in morphea and
systemic sclerosis [91]. It has also been proposed that
ECDS and PHA may be related to a neuro-vasculitis
[2,46,47,74]. A study of 41 PHA patients with light
microscopy performed on 19 tissue specimens and ultra-
structural analysis on 6 patients led to the theory that
lymphocytic neuro-vasculitis caused by chronic cell-
mediated vascular injury and incomplete endothelial
regeneration along branches of the trigeminal nerve is
central to the pathogenesis of PHA [81]. While not
proven, this may contribute to the pathogenesis of this
disorder.
There have also been reports of PHA following injury
leading to a possible trauma-induced hypothesis [98,99].
In fact, many of the studies focusing on PHA and ECDS
have noted trauma in a significant cohort of their study
population. The large survey found 27% of responders
had a childhood head injury; however, only 12% of
responders had injuries that seemed relevant to the
authors [5]. Similarly, Sommer et al. found 33% had a
preceding injury including sclerotic lesions after a
hematoma and secondary to an insect bite [17]. Caution
must be used when interpreting this data, however, as
these are relatively common occurrences, and there may
be a fair amount of responder bias.
Infectious etiologies have also been proposed in the
pathogenesis of PHA. It has been suggested that a Bell’s
palsy or herpes zoster in the trigeminal distribution may
be associated with PHA; however, studies have not been
able to corroborate this theory [100]. The coexistence of
Borrelia burgdorferi antibodies and Lyme infection have
been described in European patients with morphea;
however, recent studies, in the United Kingdom, United
States, and Turkey have not supported this association
[101-105]. Of the 12 German cases of PHA reviewed by
Sommer et al, none had antibodies to Borrelia [17]. A
recent study of 21 PHA patients and 6 with ECDS, along
with 21 matched controls in Mexico did not show an
association between Anti-Borrelia IgG antibodies and PHA,
although Lyme disease is uncommon in this geographic
location [106]. Other studies from various locations in
North America also failed to show a direct association
between Borrelia and morphea [107-111].
Lastly, sympathetic hyperactivity and dysregulation has
been proposed as a potential pathogenic mechanism in
the development of PHA [18,112,113]. A captivating
animal experiment by Resende et al. followed cats, dogs,
and rabbits for one year after ablation of the superior
cervical ganglion at the age of 30 days old. The authors
Tolkachjov et al. Orphanet Journal of Rare Diseases  (2015) 10:39 Page 8 of 13found the altered animals to have evidence of localized alo-
pecia, corneal ulceration, keratitis, strabismus, enophthal-
mos, ocular atrophy, hemifacial atrophy and slight bone
atrophy on the side of the sympathectomy, all potential
findings seen in PHA patients [114]. PHA was also induced
following a similar experiment in a rat model in 1960 [115].
These associations, however, have not been demonstrated
in human patients.
With the current body of evidence, an acquired eti-
ology to PHA is accepted, but familial cases have also
rarely been described [113,116,117]. The aforementioned
global survey of individuals with PHA found six patients
(3%) had family members with facial asymmetry, with
only one of these six responders with a first degree
relative demonstrating involvement [5]. Autosomal
dominant inheritance with incomplete penetrance has
been suggested, but no support for this hypothesis has
been provided to this point [118,119]. Hence, genetic
counseling is recommended in individual cases of PHA.
The lack of an etiology consensus and explanation of
pathogenesis of PHA also make a defined pattern of in-
heritance unlikely. In summary, a distinct etiology of
PHA is still elusive; however, a combination of auto-
immune, vascular, and autonomic dysfunction is likely.
Differential diagnosis
The differential diagnosis of PHA includes other forms of
juvenile localized scleroderma, Rasmussen encephalitis,
Barraquer-Simons syndrome, congenital hemiatrophy, and
primary hemifacial hypertrophy.
Rasmussen encephalitis (RE) presents with unilateral
cerebral hemisphere destruction with intractable focal
seizures and progressive neurologic deficits. Pathology
from the involved cerebral tissue shows chronic inflam-
mation [120]. The similar ages of onset, unilateral char-
acteristics, and epilepsy occurrence may account for the
multiple reports of associations of RE and PHA and the
difficulty of differentiating these processes [41,120-124].
In fact, some authors suggest an overlap in the disorders,
especially in the cases of PHA that are complicated by
seizures [41,120]. Patients with RE alone usually present
with hemiparesis and intractable seizures [123]. The
clinical hemiatrophy has only been described in PHA pa-
tients with coexisting RE or ECDS [41,120,122,123,125].
Additionally, brain biopsies of RE show distinct findings
of neuronal loss, reactive blood vessels, and a pale back-
ground with neutrophils and chronic inflammatory cells
[123]. Brain biopsies are not typically done in PHA. The
clinical, and if needed, histopathological differences
separate these two syndromes; however, coexistence of
RE and PHA is possible.
Baraquer-Simons syndrome is an acquired partial pro-
gressive cephalothoracic lipodystrophy that presents with
a gradual onset of symmetrical bilateral subcutaneous fatloss from the face, neck, upper extremities, thorax, and
abdomen but sparing the lower extremities. Central ner-
vous system findings of deafness, epilepsy, and intellec-
tual disability have also been described [126]. The
bilateral nature of this disease and systemic involvement
of the kidneys may differentiate these processes. How-
ever, associations of Baraquer-Simons lipodystrophy
and scleroderma are also described [127].
Hemifacial hypertrophy, formerly termed primary
hemifacial hypertrophy, is a rare asymmetric enlarge-
ment of half of the head without enlargement of other
body parts [128,129]. While there is unilateral face
enlargement instead of atrophy as seen in PHA, this
disorder may be considered in the clinical differential
diagnosis of an asymmetric unilateral facial deformity.
Other clinical mimickers of PHA are fat necrosis,
whether from infection such as bulbar poliomyelitis
[130], trauma, or connective tissue disease, and congenital
deformities such as “wry neck” [131]. Congenital hemia-
trophy has been used interchangeably with PHA; however,
it is likely a different process [16,132].
Treatment
Treatment for PHA can be challenging. The primary
aim is to stop the active disease process. Methotrexate
(MTX) is the standard therapy for active disease. MTX
dosing is not standardized and ranges from 0.3-1 milli-
grams/kilogram/week (mg/kg/wk) with a maximum dose
of 25 mg weekly in either an oral or injectable form. The
MTX is often combined with oral prednisone over the
first three months due to the fact that the methotrexate
has a delayed effect on inflammation and fibrosis. Most
regimens call for two months of prednisone at 1 mg/kg/
day with a taper to be done during the third month.
Pulsed high dose IV methylprednisone has also been
explored using 1000 mg for three days monthly for
6 months. The goal with this approach is to gain the
anti-inflammatory effects of corticosteroids without the
large side-effect profile. A long course of therapy is
typically required as relapse is frequently seen with
shorter courses of therapy. The specific length of therapy
required to reduce relapse is unknown, and likely varies
from patient to patient. Current evidence supports a
12-24 month course of methotrexate being most effect-
ive in inducing prolonged remission [1,23,83,132-136].
Isolated case reports of other immunosuppressive
agents such as mycophenolate mofetil, cyclosporine,
and cyclophosphamide have shown variable success
in patients who have failed treatment with MTX
[135,137,138]. The use of antimalarial agents has also
been described with some efficacy in a limited number
of cases [1]. Ultraviolet-A (UVA) and psoralen com-
bined with ultraviolet A (PUVA) therapy have been
shown to be effective in treatment of localized
Tolkachjov et al. Orphanet Journal of Rare Diseases  (2015) 10:39 Page 9 of 13scleroderma [139,140]. PUVA has been reported to arrest
disease activity in isolated reports of PHA [103,141].
Surgical treatment for PHA often requires a multi-
specialty approach with repeated procedures, depending
on degree of involvement. The therapeutic goal of
surgery for PHA patients is to minimize psychosocial
effects, and to correct the appearance and function of
involved facial structures [90,142-145]. Timing of surgi-
cal intervention in patients with PHA has been debated.
Most experts recommend that procedural therapy be
delayed until disease progression has halted or plat-
eaued in order to avoid multiple surgeries as defects
progress and because of the need for a stable skeletal
foundation [146-152]. However, others argue for earlier
intervention despite active disease due to the psycho-
social difficulties facing patients with PHA, promotion
of normal development of facial structures, and be-
cause most patients with PHA require multiple surger-
ies [144,145]. Ego-dystonic feelings, loss of confidence
due to appearance, and bullying are the primary rea-
sons behind pursuing surgical therapy [145]. In one
study patients who had earlier surgical intervention
had higher satisfaction scores [144], however the utility
and timing of surgical procedures must be evaluated on
an individual basis.
If surgical therapy is indeed delayed until disease
burns out, proper mandibular development and paral-
lelism of facial planes can be guided with orthodontic
rehabilitation and orthodontic appliances [142,143].
For mild to moderate atrophy, fat grafting, as well as
lipoinjection and other soft tissue fillers, can be
employed [142,144,149,153,154]. For more severe atro-
phy, a combined approach of skeletal and soft tissue
augmentation is often recommended. Bone paste cra-
nioplasty, autologous fat infections, dermal fat grafts
and adipofascial flaps can also be used to correct large
volume atrophy [144,145,155]. Additionally, the use of
bone grafts and biocompatible porous polyethylene
implants can be used to correct skeletal deformity
[145,154,155]. Eyebrow lifting, Z-plasty, lip repair,
nasal reconstruction, eyebrow repair, face-lift, lip aug-
mentation, hair transplant, and other adjuvant proce-
dures can also be used to create a better cosmetic
outcome [144,145,155].Conclusion
Progressive hemifacial atrophy, or Parry-Romberg syn-
drome, is a slowly progressive and self-limited dysplasia
causing unilateral craniofacial atrophy. The close associ-
ation with morphea en coup de sabre has been investi-
gated, but no consensus on the pathogenesis of PHA is
available. We reviewed literature addressing PHA and
summarized the relevant findings.Limitations
Since the review focuses on English literature, several
large studies have been left out including 100 cases from
Mussinelli, Magri, and Origlio [156,157], and large German
reviews by Möbius in 1895, [158] Marburg [159], and
Cassirer in 1912 [160] were excluded. Multiple inter-
national case series were reviewed by Roddi et al., in 1994
[21], Archambault and Fromm in 1932, [18] Wartenberg
in 1945 [75], and Blair O. Rogers in 1964 [16]. These
publications were reviewed in detail.
Consent
Written informed consent was obtained for the publica-
tion of this report and any accompanying images.
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